The escalating opioid crisis has prompted many health systems to integrate addiction medicine services within primary-care delivery settings, with varying degrees of success.
About eight years ago, New Hyde Park, N.Y.-based Northwell Health began planning a different route. It would create a residential and outpatient treatment facility centered on addiction medicine research. When Wellbridge Addiction Treatment and Testing opens in November in Long Island, it’ll be the first of its kind in the nation.
“The possibility of having patients literally down the hall from scientists was something that I wanted,” said Andrew Drazan, CEO and co-founder of Wellbridge.
The $95 million, six-building, 40-acre campus will include 80 residential beds and a 6,000 square-foot research facility.
Twenty beds will be used for patients undergoing medically supervised detox while 40 beds will be available for monthlong rehabilitation stays. Another 20 beds will be for stays of up to three months. Nearly half of Wellbridge’s staff will be clinical professionals.